Topics

AgeX Therapeutics, Inc. Company Profile

11:49 EST 27th January 2020 | BioPortfolio

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), is a biotechnology company applying technology relating to cell immortality and regenerative biology, to aging and age-related diseases. The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are Type II diabetes, cardiac ischemia, and cancer respectively. More information on AgeX can be found on the company’s web site.


News Articles [781 Associated News Articles listed on BioPortfolio]

AgeX Therapeutics to Present at Investing in the Age of Longevity Conference

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at...

AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced that founder and CEO Michael D. West, Ph.D. is presenting at the 2...

AgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that founder and CEO Michael D. West, Ph.D. will present at

AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd.

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced the drawdown of a $1.3 million tranche...

AgeX Therapeutics to Present at Metabesity 2019

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. ...

AgeX Therapeutics to Participate at Four Conferences in January 2020

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at...

Regenerative Medicine Leader Michael H. May Joins AgeX Board of Directors

Dr. May, CEO of Canada’s Centre for Commercialization of Regenerative Medicine (CCRM), brings 20 years of sector knowledge, leadership experience, and extensive global industry and investor network...

An Interview with Dr. Michael West

At our 2019 Ending Age-related Diseases conf

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [420 Associated PubMed Articles listed on BioPortfolio]

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, th...

Measurement of mRNA therapeutics: method development and validation challenges.

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for t...

Dr E. Keith Borden: Inaugural President of the Canadian Association for Population Therapeutics.

Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics.

Metabolism: A Burning Opioid Issue in Obesity Therapeutics.

Food restriction triggers a lowering in body temperature. A new study now provides a mechanism for this process that relies on opioid signaling in the hypothalamus. These observations suggest potentia...

Clinical Trials [205 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1417 Associated Companies listed on BioPortfolio]

AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), is a biotechnology company applying technology relating to cell immortality and regenerative biology, to agi...

BioTime Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s p...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical ...

More Information about "AgeX Therapeutics, Inc." on BioPortfolio

We have published hundreds of AgeX Therapeutics, Inc. news stories on BioPortfolio along with dozens of AgeX Therapeutics, Inc. Clinical Trials and PubMed Articles about AgeX Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AgeX Therapeutics, Inc. Companies in our database. You can also find out about relevant AgeX Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...


Corporate Database Quicklinks



Searches Linking to this Company Record